A Case of Successful Allogeneic Hematopoietic Stem Cell Transplantation for HHV8-Positive Castleman’s Disease with a Review of the Literature

Objective: To investigate the long-term clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with human herpes virus 8 (HHV8)-positive multicentric Castleman’s disease (MCD). Methods: A 17-year-old female patient was admitted to Henan Provincial People’s Hospital with the complaint of febrile for half a month, headache, and enlarged superficial lymph nodes on October 5, 2010. HHV8-positive mixed cellular Castleman’s disease was found by pathological diagnosis of lymph nodes biopsy. After the administration of CHOP and Hyper-CVAD-B, the patient was still febrile, we administrated the followed COAP, two courses of VAD(Vincristine, Adriamycin, Dexamethasone), the patient received CR. Six months after CR, the patient relapsed, we administrated VAD and two courses of bortezomide+dexamethasone chemotherapy, and then the patient received PR. After that, the patient underwent allo-HSCT from his human leukocyte antigen (HLA)-matched unrelated donor after conditioning with Bu/Cy+Etoposide+Smoustin.graft-vs-host disease (GVHD) prophylaxis, which consisted of ATG (7.5 mg/kg, qd, ivdrip) from d-5 to d-2, cyclosporine (3 mg/kg/d, qd, ivdrip, for 24 h) started from day-1, MMF(0.5 g, tid, po.) started from day+1 to +28, and MTX (15 mg per time, ivdrip, d+1,+4,+7,+11). She received 3.5×106/L CD34+cells and 8.1×108/LMNC. Results: Granulocyte engraftment occurred on day+12, platelet engrafted on day+14. Bone marrow biopsy showed normalization of trilineage hematopoiesis on day+33, chimerism: 97.6%. The transplantation was successful and followed up for 7 years with CR. Conclusion: Allo-HSCT might cure patients with refractory/relapsed HHV8+ MCD.

Download Full-text

Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis

Journal of International Medical Research ◽

10.1177/0300060519864807 ◽

2019 ◽

Vol 47 (9) ◽

pp. 4522-4529

Author(s):

Yaozhu Pan ◽

Rui Xi ◽

Cunbang Wang ◽

Lei Fang ◽

Jiaofeng Bai ◽

...

Keyword(s):

Stem Cell ◽

High Risk ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Lymph Nodes ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Langerhans Cell Histiocytosis ◽

Braf V600e ◽

Hematopoietic Stem

Langerhans cell histiocytosis (LCH) is a disorder caused by clonal proliferation of CD1a+/CD207+ cells and characterized by varying degrees of organ involvement. Treatment of LCH is risk adapted; patients with multisystem disease and risk-organ involvement require more intensive therapy. Optimal therapies for multisystem, high-risk LCH remain uncertain. Recently, targeted therapy using inhibitors of mutated BRAF (the gene encoding serine/threonine-protein kinase B-Raf) has proven very effective in patients with multisystem refractory LCH. Herein, we report a case of LCH with involvement of the bones, liver, and lymph nodes. Using next-generation sequencing of the patient’s pathological sample, we identified a mutation in MAP2K1 in exon 3 (c.362G>C, p.Cys121Ser) and no mutation in BRAF; thus, high-risk, multisystem LCH with MAP2K1 mutation and wild-type BRAF was diagnosed. After four chemotherapy treatments (COEP regimen), the patient received autologous hematopoietic stem cell transplantation (auto-HSCT). Complete remission was confirmed by follow-up positron emission tomography–computed tomography, which showed no lesions in liver, lymph nodes, or bones compared with the pretreatment period. To date, the patient has sustained good health for 24 months. In conclusion, auto-HSCT may be an effective treatment option for high-risk, multisystem BRAF V600E-negative LCH.

Download Full-text

200Autologous hematopoietic stem cell transplantation for treatment of multicentric castleman's disease/poems syndrome

Biology of Blood and Marrow Transplantation ◽

10.1016/s1083-8791(03)80193-3 ◽

2003 ◽

Vol 9 (2) ◽

pp. 123

Author(s):

U. Chamarthy ◽

N. Janakiraman ◽

G. Kamboj ◽

M. Abdel Raheem ◽

K. Ray ◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Castleman’S Disease ◽

Poems Syndrome ◽

Multicentric Castleman’S Disease ◽

Hematopoietic Stem ◽

Multicentric Castleman's Disease

Download Full-text

Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD

Blood ◽

10.1182/blood-2016-08-734210 ◽

2017 ◽

Vol 129 (13) ◽

pp. 1865-1875 ◽

Cited By ~ 7

Author(s):

Sarah Mertlitz ◽

Yu Shi ◽

Martina Kalupa ◽

Carsten Grötzinger ◽

Jörg Mengwasser ◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Lymph Nodes ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Intestinal Tract ◽

Acute Gvhd ◽

Hematopoietic Stem ◽

Key Points

Key Points aGVHD after hematopoietic stem cell transplantation is associated with lymphangiogenesis in the intestinal tract and lymph nodes. Inhibition of lymphangiogenesis by antibodies against VEGFR-3 ameliorated aGVHD.

Download Full-text

Autologous hematopoietic stem cell transplantation in HIV-associated plasmablastic lymphoma: a case report

International Professional Journal Medicine ◽

10.31082/1728-452x-2020-221-222-11-12-49-52 ◽

2021 ◽

Vol 11-12 (221-222) ◽

pp. 49-52

Author(s):

Guljanat Zhunis ◽

◽

Vadim Kemaykin ◽

Jamilya Saparbay ◽

◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Lymph Nodes ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

B Cell Lymphoma ◽

Plasmablastic Lymphoma ◽

High Dose ◽

Hematopoietic Stem

Plasmablastic lymphoma (PBL) is a disease that was originally described in 1997 as a distinct subtype of diffuse large B-cell lymphoma (DLBCL), which is more common in patients with HIV infection. It is characterized by extranodal lesions, the most common of which are the oral cavity, digestive tract, and skin3. No generally accepted chemotherapy protocol for the treatment of HIV-associated PBL has been developed. Early consolidation through autologous hematopoietic stem cell transplantation (auto-HSCT) may be a treatment option for advanced patients with concurrent use of highly active antiretroviral therapy (HAART). Disease history. Patient B., 44 years old, with HIV-associated PBL-IV-stage according to AnnArbor with lesions of the alveolar process of the upper jaw, lymph nodes of the neck on the left, bronchopulmonary lymph nodes, and the lower lobe of the right lung, who after 6 courses of chemotherapy according to the standard CHOP regimen, autotransplantation of hematopoietic stem cells was performed in the first remission. Conclusion. Our clinical experience correlates with the few studies on this issue. The patient received stem cell-supported high-dose chemotherapy (HDCT) and his life expectancy is 36 months. Keywords: plasmablastic lymphoma, HIV-associated lymphomas, autologous hematopoietic stem cell transplantation.

Download Full-text